Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Sands, Jacob M, Mandrekar, Sumithra J, Kozono, David, Oxnard, Geoffrey R, Hillman, Shauna L, Wigle, Dennis A, Govindan, Ramaswamy, Carlisle, Jennifer, Gray, Jhanelle, Salama, Joseph K, Raez, Luis, Ganti, Apar, Foster, Nathan, Malik, Shakun, Bradley, Jeffrey, Kelly, Karen, Ramalingam, Suresh S, Stinchcombe, Thomas E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293026/
https://www.ncbi.nlm.nih.gov/pubmed/33878954
http://dx.doi.org/10.2217/imt-2021-0019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293026/
https://www.ncbi.nlm.nih.gov/pubmed/33878954
http://dx.doi.org/10.2217/imt-2021-0019

Ejemplares similares